Health Care
- Cost Estimate
Information About Reconciliation Legislation for Several Committees of the House of Representatives
As Passed by the Senate on August 7, 2022
- Cost Estimate
Information About Reconciliation Legislation
As Passed by the Senate on August 7, 2022
- Cost Estimate
Estimated Budgetary Effects of H.R. 2884, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
As ordered reported by the House Committee on the Judiciary on September 30, 2021
- Cost Estimate
Estimated Budgetary Effects of H.R. 2891, the Preserve Access to Affordable Generics and Biosimilars Act
As ordered reported by the House Committee on the Judiciary on September 29, 2021
- Cost Estimate
Information About H.R. 5376, the Inflation Reduction Act of 2022
As amended in the nature of a substitute (ERN22410) and posted on the website of the Senate Majority Leader on August 6, 2022
- Report
Additional Information About Prescription Drug Legislation
CBO provides additional information that Congressman Jason Smith and his colleagues requested about subtitle I of the reconciliation recommendations of the Senate Committee on Finance regarding prescription drug legislation.
- Report
Information About Cancer Drugs Covered by Part B of Medicare
CBO provides information about the use of drugs that treat cancer and that are covered by Part B of the Medicare program, identifying the top 15 such drugs on the basis of the number of enrollees that use them.
- Cost Estimate
Estimated Budgetary Effects of H.R. 5376, the Inflation Reduction Act of 2022
As Amended in the Nature of a Substitute (ERN22335) and Posted on the Website of the Senate Majority Leader on July 27, 2022
- Blog Post
CBO’s Panel of Health Advisers, 2022
CBO announces the members of the Panel of Health Advisers for the coming year.
- Report
The 2022 Long-Term Budget Outlook
The U.S. faces a challenging fiscal outlook according to CBO's extended baseline projections, which show budget deficits and federal debt held by the public growing steadily in relation to gross domestic product over the next three decades.